SCM
AYLA

Silverarc Capital Management’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Silverarc Capital Management’s Portfolio AYLA Stock Details AYLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40,956
Closed -$464K – 92
2021
Q3 		$464K Buy
40,956
+17,592
+75% +$211K 0.26% 70
2021
Q2 		$238K Buy
+23,364
New +$240K 0.11% 91

Other funds holding AYLA

Harel Insurance Investments & Financial Services
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Silverarc Capital Management's AYLA Position: Q4 2021 in Review

Silverarc Capital Management sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q4 2021, closing a stake of 40,956 shares — an estimated $464K sold.

Silverarc Capital Management first reported a position in AYLA in Q2 2021 and held it in 2 quarters. The position peaked at $464K in Q3 2021. 13 funds tracked by Wall St. Rank hold AYLA as of Q4 2021.

  • Silverarc Capital Management reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 40,956 Ayala Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $464K.
  • Silverarc Capital Management first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Silverarc Capital Management's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $464K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.